Solgate GmbH is the first startup company born out of a cooperation between CeMM and IST Austria and its mission is to develop drugs against solute carrier (SLC) proteins, the largest family of transporters, focusing on the important roles of SLCs in neurological diseases, metabolic disorders and cancer. Through a proprietary discovery platform that combines several technologies, Solgate will efficiently develop novel chemical matter against selected SLCs.